Oncolytics Biotech (ONCY) investor relations material

Mission and platform overview

• Pelareorep is a proprietary, first-in-class double-stranded RNA immunotherapeutic agent targeting gastrointestinal tumors, aiming to address significant unmet needs in oncology.

• The platform is designed to provide a tolerable immunotherapy that increases survival for patients with GI tumors.

Mechanism of action and clinical activity

• Pelareorep is delivered intravenously, evades neutralization by associating with mononuclear cells, and selectively infects tumor cells with RAS pathway mutations.

• Replication in tumor cells triggers cell lysis and an inflammatory response, activating tumor-infiltrating lymphocytes to attack the tumor.

• Demonstrated replication in nearly all evaluated tumor types, including pancreatic, colorectal, breast, and brain cancers.

• Single-agent studies showed disease control rates up to 45% and partial responses in multiple solid tumors.

Safety profile

• Evaluated in over 1,200 patients across more than 20 studies, including 300+ with GI tumors.

• Most common adverse reactions are flu-like symptoms and mild GI symptoms, with no maximum tolerated dose identified.

• Serious adverse events are rare and generally manageable; considered well-tolerated.